A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

被引:168
作者
Piekarz, R [1 ]
Bates, S [1 ]
机构
[1] NCI, Canc Therapeut Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
histone deacetylase inhibitors;
D O I
10.2174/1381612043383980
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The historic deacetylase inhibitors (HDIs) are a new class of antineoplastic agents currently being evaluated in clinical trials. While these agents have been Studied extensively in the laboratory, only recently has their mechanism of action begun to be elucidated. Several structural classes of compounds have been shown to exert histone deacetylase inhibition, including sodium n-butyrate, suberoylanilide hydroxamic acid, LAQ824, CI-994, MS-275, and depsipeptide. The HDIs have been shown to induce differentiation. to decrease cell proliferation, and to induce cell death. HDIs are thought to exert their anti-neoplastic effects by altering the expression of genes that play a role in the control of cell growth, and transformation. The HDIs have specific and well-defined effects on cancer cell,. Preliminary results from clinical trials suggest that these agents are very promising. While there were sporadic case reports of activity using the early generation HDIs, dramatic responses have recently been observed in patients with T-cell lymphomas treated with depsipeptide. one of the never agents. With the well-defined molecular effects on cancer cells, surrogate markers can be analyzed for evidence of activity and efficacy using either tumor samples or normal tissue. presented in this review are details from clinical trials with both earlier and newer generations of HDIs. Toxicities specific to this class of agents are outlined and possibilities tor rational combination therapies are discussed.
引用
收藏
页码:2289 / 2298
页数:10
相关论文
共 105 条
[1]   Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes:: possible involvement of acetylation [J].
Adachi, N ;
Nomoto, M ;
Kohno, K ;
Koyama, H .
GENE, 2000, 245 (01) :49-57
[2]   ACETYLATION + METHYLATION OF HISTONES + THEIR POSSIBLE ROLE IN REGULATION OF RNA SYNTHESIS [J].
ALLFREY, VG ;
FAULKNER, R ;
MIRSKY, AE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1964, 51 (05) :786-+
[3]   Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) [J].
Almenara, J ;
Rosato, R ;
Grant, S .
LEUKEMIA, 2002, 16 (07) :1331-1343
[4]   Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17) [J].
Amin, HM ;
Saeed, S ;
Alkan, S .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :287-297
[5]   p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].
Archer, SY ;
Meng, SF ;
Shei, A ;
Hodin, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6791-6796
[6]   Autoimmune lymphoproliferative syndrome (ALPS) [J].
Bleesing, JJH .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (03) :265-278
[7]   Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation [J].
Brooks, CL ;
Gu, W .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :164-171
[8]   Sodium butyrate/retinoic acid costimulation induces apoptosis-independent growth arrest and cell differentiation in normal and ras-transformed seminal vesicle epithelial cells unresponsive to retinoic acid [J].
Buommino, E ;
Pasquali, D ;
Sinisi, AA ;
Bellastella, A ;
Morelli, F ;
Metafora, S .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2000, 24 (01) :83-94
[9]  
Burgess AJ, 2001, MOL PHARMACOL, V60, P828
[10]   Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells [J].
Byrd, JC ;
Shinn, C ;
Ravi, R ;
Willis, CR ;
Waselenko, JK ;
Flinn, IW ;
Dawson, NA ;
Grever, MR .
BLOOD, 1999, 94 (04) :1401-1408